What we deliver
From evidence dossiers to advisory boards, every service is built to turn complex scientific work into practical, expert-validated deliverables for pharma teams.
Services for
By Team
All
Medical Affairs
Market Access
Brand & Launch
Regional Teams
By Stage
All
Pre-Launch
Launch
Mature Brand
Any Stage
By Expertise
All
Access & Localization
Evidence Generation
Launch Support
KOL & Expert Engagement
Congress & Publications
Omnichannel Content
14 services shown
Evidence & Medical Writing
Evidence Dossiers
Structured evidence packages adapted for your local market — local comparators, treatment guidelines, and clinical data reframed for affiliate medical and access teams across EMEA.
Medical AffairsMarket AccessRegional
See cases →
Learn more →
Clinical Summaries
Concise, field-ready summaries of key clinical trial data — designed for Medical Science Liaisons, medical directors, and internal pharma teams.
Medical Affairs
See cases →
Learn more →
Medical Writing
Publication-grade manuscripts, congress abstracts, scientific posters, and regulatory documents — written by MDs and PhDs with deep therapeutic area expertise.
Medical Affairs
See cases →
Learn more →
Evidence Communication
Visual abstracts, medical infographics, interactive slide decks, and omnichannel content — transforming complex clinical data into accessible formats for every stakeholder.
Medical AffairsBrand & Launch
See cases →
Learn more →
Literature Monitoring
Systematic literature surveillance and rapid post-congress/post-publication updates via PubMed and medical databases — keeping your evidence base current.
Medical Affairs
See cases →
Learn more →
Market Access & Value
Payer Dossiers
Country-specific value dossiers, HTA submissions, AMCP-format dossiers, and payer-facing evidence packages — adapted for local health technology assessment requirements.
Market Access
See cases →
Learn more →
KOL & Expert Engagement
Advisory Boards
End-to-end advisory board management and Delphi consensus projects — from KOL recruitment and protocol design to transcripts, summary reports, and publication-ready outputs.
Medical Affairs
See cases →
Learn more →
KOL Programmes
Structured KOL engagement strategies — speaker programmes, expert mapping, scientific collaboration, and relationship management across therapeutic areas and markets.
Medical AffairsBrand & Launch
See cases →
Learn more →
Launch & Strategy
Launch Evidence Toolkit
Complete pre-launch evidence package — core scientific narrative, MSL slide decks, payer FAQ documents, and KOL briefing materials, aligned across functions from day one.
Brand & LaunchMedical Affairs
See cases →
Learn more →
Publication Planning
End-to-end publication strategy — author coordination, target journal selection, manuscript submission management, and timeline tracking for pharma publication plans.
Medical Affairs
See cases →
Learn more →
Presentations & Content
Slide Decks
From literature search to final polished design — scientific presentations in any format: PPTX, HTML, interactive quizzes. Professional redesign with unified pharma branding and data visualization.
Medical AffairsBrand & Launch
See cases →
Learn more →
Source Verification
Reference sourcing, fact-checking, and scientific annotation for pharma material approval (MLR review) systems. Ensuring every claim is traceable, accurate, and compliance-ready.
Medical Affairs
See cases →
Learn more →
Data & Real-World Evidence
Biostatistics
Clinical dataset analysis, data cleaning, statistical programming, and data extraction from large unstructured sources including EHR, physician notes, and medical registries.
Medical AffairsMarket Access
See cases →
Learn more →
RWD/RWE Studies
Full-service RWE support from protocol synopsis to final publication — AI-enhanced EDC setup, observational study design, real-world data collection, statistical analysis, and reporting.
Medical AffairsMarket Access
See cases →
Learn more →
Real work. Measurable outcomes.
Selected case studies
Ribociclib post-ASCO update: field-ready summary for 12 EMEA markets in 48 hours
✓ MSL teams received updated materials within 48h of congress close
Delphi consensus on treatment sequencing — 5 scientific societies endorsed
✓ 5 scientific societies endorsed the consensus document
PKU patient identification: diagnosed patients doubled within 12 months
✓ Diagnosed patients doubled within 12 months of launch
AI infrastructure
AI-powered.
Expert-validated.
We built AI workflows into our daily practice — not as a marketing claim, but as the infrastructure that lets our medical experts deliver faster without cutting corners.
Research
Structured PubMed queries with narrative or table outputs
Monitoring
Weekly literature digests by drug, target, or topic
AI-Enhanced EDC
Electronic data capture with AI-assisted structuring of unstructured records
Fact-Checker
Claim verification against your source documents
AI accelerates. Our experts validate.
Every output goes through expert medical review before it reaches your team. AI handles structure and speed — we handle scientific judgement and MLR readiness.
// Query: ribociclib OS data MONALEESA 2023–24
search("ribociclib overall survival", {
years: [2023, 2024],
output: "structured_table"
})
// 847 records → 23 relevant
Processing 847 records...
Evidence Summary
MONALEESA-2 updated OS (NEJM 2023): median OS 63.9 mo vs 51.4 mo (HR 0.76, 95% CI 0.63–0.93). Benefit maintained across all pre-specified subgroups...
Need a specific
deliverable?
deliverable?
Tell us what you're working on — we respond within 24 hours with a tailored scope and timeline.
SolveLetter · Monthly insights
From the field:
evidence & practice
Advisory Boards
What Makes an Advisory Board Truly Insightful? New Trends, Smarter Ideas, and Next-Gen Formats
An advisory board is one of the most intelligent and powerful tools in the pharma arsenal. With the right event architecture, it helps generate valuable insights and build trust within the medical community.
Jun 2025 · SolveLetter #3
Read →
Evidence Strategy
Why Do RWE and RWD Projects Face Challenges, and How Can We Avoid Them?
With evidence generation becoming a key performance indicator for many medical affairs teams, interest in RWE approaches is growing rapidly. Based on experience across a dozen projects, we’ve gathered insights that might be useful.
Apr 2025 · SolveLetter #2
Read →
KOL Engagement
How to Increase Expert (KOL) Engagement in Congresses, Conferences, and Seminars?
Expert engagement at live events is declining. We explore practical solutions and formats that drive real KOL participation and meaningful scientific dialogue.
Feb 2025 · SolveLetter #1
Read →